Segment Information

3 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating loss, and depreciation and amortization were as follows:

	Three Months Ended December 31,
(In thousands)	2023			2022
Revenue:
Medical Device	$	23,545		$	19,018
In Vitro Diagnostics		7,007			5,915
Total revenue	$	30,552		$	24,933
Operating loss:
Medical Device	$	(224	)	$	(7,235	)
In Vitro Diagnostics		3,124			2,948
Total segment operating income (loss)		2,900			(4,287	)
Corporate		(3,222	)		(2,942	)
Total operating loss	$	(322	)	$	(7,229	)
Depreciation and amortization:
Medical Device	$	2,054		$	1,953
In Vitro Diagnostics		97			77
Corporate		182			92
Total depreciation and amortization	$	2,333		$	2,122

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.